专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20050059685A1 Pyridopyrimidine compounds and their uses 审中-公开
标题翻译：吡啶并嘧啶化合物及其用途
公开(公告)号：US20050059685A1
公开(公告)日：2005-03-17
申请号：US10921293
申请日：2004-08-19
申请人： Marc McKennon , J. Klein , Michael Coon
发明人： Marc McKennon , J. Klein , Michael Coon
IPC分类号： A61P11/06 , A61P17/06 , A61P19/02 , A61P29/00 , A61P43/00 , C07D471/04 , A61K31/519 , C07D487/02
CPC分类号： C07D471/04
摘要： Novel pyridopyrimidine-based compounds are found to be useful for the treatment or prevention of symptoms or manifestations associated with diseases or disorders affected by cytokine intracellular signaling.
摘要翻译：发现新的吡啶并嘧啶类化合物可用于治疗或预防与受细胞因子细胞内信号传导影响的疾病或病症相关的症状或表现。

2. 发明申请

US20070178134A1 Pyridines and uses thereof 审中-公开
标题翻译：吡啶类及其用途
公开(公告)号：US20070178134A1
公开(公告)日：2007-08-02
申请号：US11724459
申请日：2007-03-14
申请人： Feng Hong , J. Klein
发明人： Feng Hong , J. Klein
IPC分类号： A61K31/53 , A61K31/513 , A61K31/4412 , A61F2/02
CPC分类号： C07D213/74 , A61L27/34 , A61L31/10 , C07D213/75
摘要： The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
摘要翻译：本发明涉及吡啶及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

3. 发明申请

US20050032748A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same 审中-公开
标题翻译：用于抑制白细胞介素-12信号的治疗化合物及其使用方法
公开(公告)号：US20050032748A1
公开(公告)日：2005-02-10
申请号：US10909321
申请日：2004-08-03
申请人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
发明人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
IPC分类号： A61K31/00 , C07D473/04 , C07D473/06 , C07D487/04 , C07D495/04 , C07D513/04 , A61K31/675 , A61K31/519 , A61K31/522
CPC分类号： C07D473/04 , A61K31/00 , C07D473/06 , C07D487/04 , C07D495/04 , C07D513/04
摘要： Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N,N(R3) and S. Each R1, R2 and R3 is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
摘要翻译：发现具有与五元环结构稠合的六元环结构的新型杂环化合物可用于治疗和预防与受白细胞介素-12（“IL-12”）影响的紊乱相关的症状或表现，，例如，Th1细胞介导的疾病。治疗化合物，药学上可接受的衍生物（例如分解的对映异构体，非对映异构体，互变异构体，其盐和溶剂合物）或其前药具有以下通式：每个X，Y和Z独立地选自C （R 3），N，N（R 3）和S.每个R 1，R 2和R 3是取代或未取代的，并且独立地选自氢，卤素，氧代，C（1-20）烷基，C （1-20）羟基烷基，C（1-20）硫代烷基，C（1-20）烷基氨基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧羰基，C（1 -20）氨基烷基，C（1-20）三氨基烷基，C（1-20）四氨基烷基，C（5-15）氨基三烷氧基氨基，C（1-20）烷基酰氨基，C（1-20））烷基酰氨基烷基，C（1-20）酰氨基烷基，C（1-20）乙酰氨基烷基，C（1-20）烯基，C（1-20）炔基，C（3-8）烷氧基，C（1-11）烷氧基烷基，和C（1-20）二烷氧基烷基。

4. 发明申请

US20080064700A1 Aryl triazines as LPAAT-beta inhibitors and uses thereof 失效
标题翻译：芳基三嗪作为LPAAT-β抑制剂及其用途
公开(公告)号：US20080064700A1
公开(公告)日：2008-03-13
申请号：US11890746
申请日：2007-08-06
申请人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott Jenkins , J. Klein , Anil Kumar , John Tulinsky
发明人： Rama Bhatt , Baoqing Gong , Feng Hong , Scott Jenkins , J. Klein , Anil Kumar , John Tulinsky
IPC分类号： A61K31/53 , A61P35/00 , C07D251/42 , C07D251/48 , C07D403/10 , C07D407/02 , C12N5/00
CPC分类号： C07D403/12 , C07D251/16 , C07D251/18 , C07D251/22 , C07D405/12
摘要： The invention relates to aryl triazines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.
摘要翻译：本发明涉及芳基三嗪及其用途，包括抑制溶血磷脂酸酰基转移酶β（LPAAT-β）活性和/或细胞例如肿瘤细胞的增殖。

5. 发明申请

US20060211713A1 Compounds having selective hydrolytic potentials 审中-公开
标题翻译：具有选择性水解电位的化合物
公开(公告)号：US20060211713A1
公开(公告)日：2006-09-21
申请号：US11370164
申请日：2006-03-08
申请人： David Porubek , Anil Kumar , Charles Bredl , J. Klein
发明人： David Porubek , Anil Kumar , Charles Bredl , J. Klein
IPC分类号： A61K31/522 , A61K31/52 , C07D473/02 , C07D473/04
CPC分类号： C07D473/04 , C07D473/10
摘要： Disclosed are compounds having selective hydrolytic potential. The disclosed compounds are useful as compounds having selective stability and are capable of undergoing programmed hydrolysis in biologic systems.
摘要翻译：公开了具有选择性水解电位的化合物。所公开的化合物可用作具有选择性稳定性且能够在生物系统中进行程序水解的化合物。

6. 发明申请

US20050182102A1 Pyridines and uses thereof 失效
公开(公告)号：US20050182102A1
公开(公告)日：2005-08-18
申请号：US11056777
申请日：2005-02-11
申请人： Feng Hong , J. Klein
发明人： Feng Hong , J. Klein
IPC分类号： A61L27/34 , A61L31/10 , C07D213/74 , A61K31/4439 , C07D43/02
CPC分类号： C07D213/74 , A61L27/34 , A61L31/10 , C07D213/75
摘要： The invention relates to pyridines and uses thereof, including to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity and/or proliferation of cells such as tumor cells.

7. 发明申请

US20070072856A1 LPAAT-beta inhibitors and uses thereof 失效
标题翻译： LPAAT-β抑制剂及其用途
公开(公告)号：US20070072856A1
公开(公告)日：2007-03-29
申请号：US11601513
申请日：2006-11-16
申请人： Baoqing Gong , John Tulinsky , Lynn Bonham , J. Klein , Robert Finney , David Hollenback , Scott Shaffer , Norina Tang , Thayer White , David Leung
发明人： Baoqing Gong , John Tulinsky , Lynn Bonham , J. Klein , Robert Finney , David Hollenback , Scott Shaffer , Norina Tang , Thayer White , David Leung
IPC分类号： A61K31/5377 , A61K31/53 , C07D413/02 , C07D251/48
CPC分类号： C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
摘要： The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPAAT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.
摘要翻译：本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPAAT-β）活性的用途。本发明还涉及使用所述三嗪治疗癌症的方法。本发明还涉及用于筛选LPAAT-β活性的方法。

8. 发明申请

US20060035896A1 LPAAT-beta inhibitors and uses thereof 失效
标题翻译： LPAAT-β抑制剂及其用途
公开(公告)号：US20060035896A1
公开(公告)日：2006-02-16
申请号：US11224340
申请日：2005-09-12
申请人： Lynn Bonham , J. Klein , Robert Finney , David Hollenback , Scott Shaffer , Norina Tang , Thayer White , David Leung , Baoqing Gong , John Tulinsky
发明人： Lynn Bonham , J. Klein , Robert Finney , David Hollenback , Scott Shaffer , Norina Tang , Thayer White , David Leung , Baoqing Gong , John Tulinsky
IPC分类号： A61K31/5377 , A61K31/53 , C07D413/02 , C07D403/02
CPC分类号： C07D251/70 , C07D251/50 , C07D251/52 , C07D251/54 , C07D251/58
摘要： The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase β (LPMT-β) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-β activity.
摘要翻译：本发明涉及三嗪及其用于抑制溶血磷脂酰基转移酶β（LPMT-β）活性的用途。本发明还涉及使用所述三嗪治疗癌症的方法。本发明还涉及用于筛选LPAAT-β活性的方法。

9. 发明申请

US20050049262A1 Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same 审中-公开
标题翻译：用于抑制白细胞介素-12信号的治疗化合物及其使用方法
公开(公告)号：US20050049262A1
公开(公告)日：2005-03-03
申请号：US10918709
申请日：2004-08-16
申请人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
发明人： J. Klein , Stephen Klaus , Anil Kumar , Baoqing Gong
IPC分类号： A61K31/00 , C07D239/54 , C07D473/04 , C07D473/06 , C07D473/10 , C07D487/04 , C07D495/04 , C07D513/04 , A61K31/519 , A61K31/522
CPC分类号： C07D239/54 , A61K31/00 , C07D473/04 , C07D473/06 , C07D473/10 , C07D487/04 , C07D495/04 , C07D513/04
摘要： Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by lnterleukin-12 (“IL-12”) intracellular signaling, such as, for example, Th1 cell-mediated disorders. The therapeutic compounds, pharmaceutically acceptable derivatives (e.g., resolved enantiomers, diastereomers, tautomers, salts and solvates thereof) or prodrugs thereof, have the following general formula: Each X, Y and Z are independently selected from a member of the group consisting of C(R3), N, N(R3) and S. Each R1, R2 and R3 is substituted or unsubstituted and is independently selected from a member of the group consisting of hydrogen, halo, oxo, C(1-20)alkyl, C(1-20)hydroxyalkyl, C(1-20)thioalkyl, C(1-20)alkylamino, C(1-20)alkylaminoalkyl, C(1-20)aminoalkyl, C(1-20)aminoalkoxyalkenyl, C(1-20)aminoalkoxyalkynyl, C(1-20)diaminoalkyl, C(1-20)triaminoalkyl, C(1-20)tetraaminoalkyl, C(5-15)aminotrialkoxyamino, C(1-20)alkylamido, C(1-20)alkylamidoalkyl, C(1-20)amidoalkyl, C(1-20)acetamidoalkyl, C(1-20)alkenyl, C(1-20)alkynyl, C(3-8)alkoxyl, C(1-11)alkoxyalkyl, and C(1-20)dialkoxyalkyl.
摘要翻译：发现具有与五元环结构稠合的六元环结构的新型杂环化合物可用于治疗和预防与白细胞介素-12（“IL-12”）受细胞内信号传导的疾病相关的症状或表现，例如，例如，Th1细胞介导的疾病。治疗化合物，药学上可接受的衍生物（例如分解的对映异构体，非对映异构体，互变异构体，其盐和溶剂合物）或其前药具有以下通式：每个X，Y和Z独立地选自C （R 3），N，N（R 3）和S.每个R 1，R 2和R 3是取代或未取代的，并且独立地选自氢，卤素，氧代，C（1-20）烷基，C （1-20）羟基烷基，C（1-20）硫代烷基，C（1-20）烷基氨基，C（1-20）烷基氨基烷基，C（1-20）氨基烷基，C（1-20）氨基烷氧羰基，C（1 （1-20）氨基烷基，C（1-20）四氨基烷基，C（5-15）氨基三烷氧基氨基，C（1-20）烷基酰氨基，C（1-20）烷基氨基烷基，C（1-20））烷基酰氨基烷基，C（1-20）酰氨基烷基，C（1-20）乙酰氨基烷基，C（1-20）烯基，C（1-20）炔基，C（3-8）烷氧基，C（1-11）烷氧基烷基，和C（1-20）二烷氧基烷基。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式